The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

Robert F. Kennedy Jr., nominated to be health secretary, seemed unfamiliar with the particulars of the massive insurance ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...

Pharmaceutical executives are near unanimous (with 68% strongly agreeing and 31% somewhat agreeing) in their concern about a marked increase in theft, fraud, and/or attacks in the pharmaceutical ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...